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Background: Psoriasis is a common chronic inflammatory disease of the skin. We sought to characterize and
compare the cutaneous microbiota of psoriatic lesions (lesion group), unaffected contralateral skin from psoriatic
patients (unaffected group), and similar skin loci in matched healthy controls (control group) in order to discern
patterns that govern skin colonization and their relationship to clinical diagnosis.
Results: Using high-throughput 16S rRNA gene sequencing, we assayed the cutaneous bacterial communities of
51 matched triplets and characterized these samples using community data analysis techniques. Intragroup Unifrac β
diversity revealed increasing diversity from control to unaffected to lesion specimens. Likewise, principal coordinates
analysis (PCoA) revealed separation of the lesion samples from unaffected and control along the first axis, suggesting
that psoriasis is a major contributor to the observed diversity. The taxonomic richness and evenness decreased in
both lesion and unaffected communities compared to control. These differences are explained by the combined
increased abundance of the four major skin-associated genera (Corynebacterium, Propionibacterium, Staphylococcus,
and Streptococcus), which present a potentially useful predictor for clinical skin type. Psoriasis samples also showed
significant univariate decreases in relative abundances and strong classification performance of Cupriavidus, Flavisolibacter,
Methylobacterium, and Schlegelella genera versus controls. The cutaneous microbiota separated into two distinct
clusters, which we call cutaneotypes: (1) Proteobacteria-associated microbiota, and (2) Firmicutes-associated and
Actinobacteria-associated microbiota. Cutaneotype 2 is enriched in lesion specimens compared to control (odds ratio 3.52
(95% CI 1.44 to 8.98), P <0.01).
Conclusions: Our results indicate that psoriasis induces physiological changes both at the lesion site and at the systemic
level, which select for specific differential microbiota among the assayed clinical skin types. These differences in microbial
community structure in psoriasis patients are potentially of pathophysiologic and diagnostic significance.
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Psoriasis is a chronic inflammatory skin disease of
unknown etiology. The initial presentation and periodic
exacerbations of psoriasis likely result from unidentified
environmental exposures in individuals with genetic
predisposition. The pathophysiology of psoriasis in part
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distribution, and reproduction in any mediumresponse directed against unascertained pathogens [1].
It is intriguing to surmise that in some patients, the
colonizing microbiota of the skin elicit and perpetuate
psoriasis. The identification of such ‘offending’ microbiota
potentially could lead to early diagnostics, disease-modifying
or, perhaps, curative therapies for this often devastating
condition.
There have been only limited studies of the microbiota
in psoriasis patients using molecular methods for the
detection of bacterial and fungal taxa [2-5]. Such studies
have involved relatively small numbers of subjects [2],
relatively low-throughput bacterial community identification
technologies [3-5] and unmatched study designs [2].ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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availability of affordable high-throughput sequencing
techniques for bacterial community identification.
Variation in composition of the cutaneous microbiome has
been studied from the ecological [6-8], anthropological [9],
biomedical forensics [10], as well as medical standpoints
[2,11-17]. Most notably, the major effort through the
Human Microbiome Project (HMP) of the US National
Institutes of Health (NIH) has resulted in microbial identi-
fication of communities in 300 healthy individuals across
multiple body sites including several skin sites [16,18,19].
As one of the HMP demonstration projects, we sought
to compare the cutaneous microbiota of psoriasis subjects
with those from matched healthy controls in a disease-
specific psoriasis cohort. The delineation of a psoriasis-
specific microbiome signature is an attempt to understand
a potential pathophysiologic influence of the microbiome
on psoriatic disease. Further, if a specific microbiomal
composition drives the psoriatic pathophysiology there
would be potential to treat this disease by ‘normalizing’ the
abnormal microbiome.
Because the cutaneous microbiota is complex, and its
composition is site specific, we matched the affected
lesion skin samples with unaffected contralateral skin
samples from the same subject. For each psoriasis subject, a
demographically matching control subject was selected and
a specimen from that subject was obtained so as to match
the affected body site. Thus, we collected and analyzed
our data as triplets of lesion, clinically unaffected, and
control specimens. To reduce the variability associated
with treatment, we excluded subjects with recent antibiotic
and other relevant treatments. A small subset of subjects
was similarly followed longitudinally to study the effect of
beginning antipsoriatic therapy on the composition of the
microbiota.
Methods
Study population and subject specimen matching
Between June 2008 and September 2011, we obtained
consent (using the model consent forms for the HMP
demonstration projects) and enrolled a total of 199 subjects
(75 patients with psoriasis and 124 healthy controls) with
ethical approval from New York University School of
Medicine Institutional Review Board (IRB #08-709).
The subjects were recruited from the same geographic
region (NYC) and same clinic at NYU. Among the
patients with psoriasis, 57 (76%) had not been exposed to
antibiotics or received treatment relevant to psoriasis for
at least 1 month before skin samples were obtained.
Among the healthy controls, 112 (90.3%) had not been
exposed to antibiotics or received treatments relevant to
psoriasis for at least 1 month before skin samples were
obtained. Psoriasis subjects receiving antibiotics less than
1 month before enrollment were excluded from furtheranalysis, only six (11.8%) of the remaining subjects had
taken any antibiotics in the preceding year. When we
reviewed the control subjects who actually were included,
none had received antibiotics in the 12 months prior
to sampling. A total of 54 (72%) patients with psoriasis
were studied by swabbing of the affected (lesion) and
unaffected (unaffected) sites (see section on Specimen
collection for details).
For these subjects, we sought control subjects of the
same gender and ethnicity, and of similar age (± 5 years),
from whom a cutaneous specimen was obtained in a region
proximate to the site of the psoriasis lesion. In total, we
obtained matching specimens from 37 (29.8%) of the
control subjects. One or more sites from each of these
controls were matched to the lesions in the 54 subjects with
psoriasis. A control subject could be matched to more than
one patient, since we also matched for cutaneous site.
However, each control cutaneous site was uniquely mapped
to only one triplet, thus there was no duplication of
specimens in the analysis. In each of 48 matched
pairs, the 2 sites match, but in 6 sites we matched a back
specimen with an abdomen, which are relatively similar in
composition in healthy skin. The final analyses were
performed on a set of 51 triplets, which had adequate
depth of sequencing (>1,000 sequences per sample).
The resulting set of 51 triplets contained samples from
sites that are characteristic of where typical psoriatic
lesions occur in the general population. All of the sites were
of the dry or sebaceous cutaneous microenvironments. We
grouped the exact location of the specimen by proximity
to other samples into four categories: body, head, upper
extremities and lower extremities. Upper and lower
extremities contained only samples of the dry cutaneous
microenvironment, while all head samples and 8 out of
12 body trunk samples were characterized as sebaceous.
A table describing the matching of psoriasis lesions to
control sites and skin environment is provided in
Additional file 1: Table S1.
Although psoriasis affects each gender equally, our
final set of subjects consisted of 75% males. The bias
towards men being sampled possibly can be explained
by the fact that the medicines used in the study are often
not used in women of childbearing age, thus limiting the
enrollment of women.
Longitudinal study
A subset of psoriatic patients (n = 17) and age, gender,
and ethnicity matched controls (n = 15) were followed
prospectively for a period of 36 weeks and skin samples
were obtained at baseline, and then after the cases
started clinically indicated treatment for psoriasis, at
12 weeks, and 36 weeks (Additional file 1: Table S2).
The 12-week mark was included in order to detect any
initial effect of treatment on the microbiota, while the
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stability of the changes observed at 12 weeks. For the
17 patients, the treatments were adalimumab (6),
methotrexate (5), methotrexate and adalimumab (4), and
other (2) (methotrexate and cyclosporine and adalimumab
switched to Stelara (ustekinumab)). Although adalimumab
blocks proinflammatory cytokines, whereas methotrexate
alters adenosine metabolism, both agents have similar net
effects in downregulating inflammation. As such, these
two treatments may similarly affect the skin microbiota,
through their shared anti-inflammatory effects, moving it
to a more normal composition. While the goal of this
study is to examine the maximal number of subjects
with similar demographics, clinical skin condition, and
treatment status, the potential differences in microbiota
composition due to each treatment course may need to be
studied in larger uniform cohorts.
Psoriasis diagnosis and characteristics of populations
Patients were diagnosed with chronic plaque psoriasis in a
dermatology clinic, and psoriasis was clinically classified
based on characteristic morphologic features of the
individual skin lesions and their distribution on the
body. For each patient, disease duration, percentage
cutaneous involvement, Psoriasis Area and Severity Index
(PASI) and physician global assessment (PGA) scores were
recorded. Means of severity scores for the subjects were
PASI: 8.7 (± 10.1 SD), PGA: 6.6 (± 6.9 SD), and body
surface area (BSA): 9.4 (± 13.9 SD). The characteristics of
the control and affected study populations are given in
Additional file 1: Table S3.
Specimen collection
In patients with psoriasis, we sampled a typical psoriatic
plaque (designated as psoriasis, lesion), and as a reference
site, a contralateral area of clinically uninvolved skin
(designated as psoriasis, unaffected). We also examined skin
from a healthy (control) person at the same approximate
cutaneous location as the psoriatic lesion. We accomplished
this by obtaining four skin swabs from each control person,
from scalp (posterior-temporal, above ear crease), inner
aspect of the elbow, lower lateral abdomen, and kneecap.
This distribution mimicked the distribution of the lesions in
most of the cases.
Methods for specimen processing have been described
[20]. In brief, a 2 × 2 cm area of the cutaneous surface at
each of the locations was sampled by swabbing the skin
with a cotton pledget that had been soaked in sterile
0.15 M NaCl with 0.1% Tween 20 (Fisher Scientific, Fair
Lawn, NJ, USA). DNA was extracted from the swab
suspensions in a PCR-free clean room by using the DNeasy
blood and tissue kit (Qiagen, Chatsworth, CA, USA); glass
beads (0.5 to 1 mm) were added to the specimens and
vortex mixed at maximum speed for 40 s, followed byDNA extraction, using the manufacturer’s protocol for
genomic DNA isolation from Gram-positive bacteria, and
samples were eluted in 100 μl AE buffer (DNeasy
Blood and Tissue kit; Qiagen). To eliminate potential
bacterial or DNA contamination of lysozyme, the lysozyme
(Sigma-Aldrich, St Louis, MO, USA) was passed through a
microcentrifuge filter (molecular mass threshold, 30,000 Da;
Amicon, Bedford, MA, USA) at 18,514 g or 20 min before
adding to the enzymatic lysis buffer.
DNA sequencing and upstream processing
Samples were prepared for amplification and sequencing
at the J. Craig Venter Institute (JCVI) Joint Technology
Center (JTC) using a protocol for 16S rRNA gene
amplification and sequencing developed as part of the
NIH Human Microbiome Project [18,21]. Negative control
experiments were performed, when we developed the
extraction protocol with Qiagen kit [22]. In short, we used
a reagent control that included all DNA extraction and
polymerase chain reaction (PCR) reagents, including the
sterile swab and the buffers, without the skin sample. This
specimen was examined in parallel using the identical
procedures as with the skin samples. After electrophoresis
and ethidium bromide staining, preparations from these
controls did not generate any visible bands. Negative
control reactions were performed for every pool of
amplicons to ensure no visible detection of amplicons
on ethidium bromide stained agarose gels. The V1 to
V3 region of the 16S rRNA gene was amplified using
forward primer 5′-AGAGTTTGATCCTGGCTCAG-3′
attached to the Roche B adapter for 454-library con-
struction and reverse primer 5′-CCGTCAATTCMTT
TRAGT-3′ attached to the Roche A adapter and a
10-nt barcode (5′-A-adapter-N (10) + 16S primer-3′).
The barcoded primer design was completed using a
set of algorithms developed at the JCVI for these pur-
poses [23,24]. PCR reactions were completed as follows
(per reaction): 2 μl of gDNA (approximately 2 to 10 ng/μl),
1× final concentration of Accuprime PCR Buffer II
(Invitrogen, Carlsbad, CA, USA), 200 nmol forward and
reverse primers, 0.75 U of Accuprime TaqDNA polymerase
high fidelity (Invitrogen), and nuclease-free water to bring
the final volume to 20 μl. PCR cycling conditions consisted
of an initial denaturation of 2 min at 95°C, 30 cycles of
20 s at 95°C, and 30 s at 56°C followed by 5 min at 72°C. A
high number of amplification cycles is standard for skin
studies because of typically low bacterial load in these
specimens [25]. A negative control (water blank) reaction
was examined after 35 cycles, and determined to be
negative for the amplicon. Samples were then quanti-
fied, cleaned, and sequenced on the Roche 454-FLX
(454 Life Sciences, Branford, CT, USA) as described
previously [21], and a read processing pipeline consisting of
a set of modular scripts designed at the JCVI were
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lution, trimming, and quality filtering, as described
previously [26]. We performed a parallel analysis of
the V3 to V5 16S rRNA gene region, but because of
amplification and sequencing depth issues there were
only 21 available triplets at this locus. Therefore, we
focused exclusively on the V1 to V3 dataset.
Downstream sequence processing and statistical analyses
After upstream processing and quality checking the
passing sequences were analyzed using QIIME scripts [27].
We first clustered the sequences into 97% identity
operational taxonomical units (OTUs) using the UCLUST
program [28]. A representative sequence from each OTU
cluster was used to assign taxonomy to the cluster using
the RDP Classifier [29] executed at 80% bootstrap
confidence cut-off. These representative sequences were
further aligned using PyNAST [30] with the Greengenes
core-set alignment template. We used the alignment
to reconstruct an approximate phylogenetic tree using
FASTTREE [31]. The obtained phylogenetic tree and
abundance tables were used to calculate unweighted and
weighted UniFrac β diversity indices [32]. The OTU abso-
lute abundance table and UniFrac β diversity matrices were
extracted from the pipeline for further analysis in the R
statistical programming environment [33]. After processing
the median sequencing depth per sample was 8,621 (IQR
5,013 to 11,412). The sequencing effort was statistically
similar across clinical skin types, body sites and cutaneous
microenvironment (Additional file 1: Figure S1).
Chimeras were checked with ChimeraSlayer [34]. In
all, 2,700 of the total 34,123 OTUs (7.9%) identified in the
study were marked as potentially chimeric. On average, the
total relative abundance (fraction of total sequences) per
sample of putatively chimeric sequences was 3% (± 2% SD).
The abundance of suspected chimera was similar across
clinical skin types, body sites and cutaneous micro-
environment (P >0.05 Kruskal-Wallis analysis of variance
(ANOVA)).
The rarefactions for richness and Shannon diversity
indices were calculated using scripts based on the commu-
nity ecology package vegan. Comparisons of intergroup
and intragroup β diversity were performed using one-way
ANOVA with the Tukey honestly significant difference
(HSD) multiple comparison correction procedure.
We used the ade4 package [35] in R to perform
Principal Coordinates Analysis (PCoA) on weighted
Unifrac distances. To avoid negative eigenvalues in the
analysis, we used the Cailliez method [36] to convert
the weighted Unifrac distance matrix into a closest
corresponding matrix with Euclidean properties, which
was further used for PCoA.
Univariate testing was performed on OTU relative abun-
dances, calculated by dividing the absolute abundances bythe total sequence count per sample analyzed. Differential
relative abundance of specific taxa and OTUs was
calculated on highly abundant taxa (mean relative
abundance >1%) using the Kruskal-Wallis test with FDR
correction for multiple testing [37]. This approach is
analogous to standard ANOVA in that the test is significant
if any pair of relative abundances (control vs unaffected,
control vs lesion, unaffected vs lesion) is different. Post hoc
pairwise testing with additional multiple testing control can
be utilized to determine which pair is different.
Multiple testing correction and compositional data issues
The fact that the relative abundances present a compos-
itional constraint violates the independence assumption.
The relevant nature of the independence violation is that
the individual significance values for the univariate tests
are now potentially positively correlated. An example of
such correlations is a situation where a statistically
significant increase in one taxon abundance between
two conditions is accompanied by a balancing decrease in
one or more other taxa to have the abundances sum to a
constant (1). However, the effect of this independence
violation on the validity of the univariate findings is only
mild for the following reasons: (1) the compositional
constraint does not remove any true positive association,
it only inflates the false negative rates, (2) false negatives
are then controlled by the FDR multiple testing correction
procedure, which is designed to take into account positive
correlations in P values; (3) the effect of compositional
constraint is minimized by the fact that we only focus on
highly abundant taxa. Therefore, we believe that this study
admits false positives at a rate similar to other genomic
analyses, and this allows for discovery of useful associations
with the phenotypes, which may be of potential diagnostic
value, but may need further validation.
We utilized univariate χ2 tests to compare the preva-
lence of specific taxa among clinical skin types. Spearman
correlation tests were used to find associations between
severity scores and taxa abundance. The P values were
adjusted for false discovery using the Benjamini-Hochberg
procedure [37]. Receiver operating characteristic curves
(ROC) were computed in R using the package ROCR [38]
and significance of the classification signal as measured by
the area under the ROC curve (AUC) was established
by Mann–Whitney test.
To establish the presence and identity of cutaneotypes
in our data, we utilized methodology identical to that
previously used for gut-microbiota enterotype classifica-
tion [39]. In short, we applied the partitioning around
medoids (PAM) method [40] to the square root of the
Jensen-Shannon divergence distances to compute optimal
clustering with given numbers of clusters (2 through 20).
The Calinski-Harabasz index [41] was used to establish
the number of cutaneotypes to optimally cluster the data.
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gap statistic [42], and is described in supplementary
materials.
Non-Euclidean multivariate analysis of variance
(MANOVA) was used to analyze the association of
microbiota with clinicodemographic variables [43]. This
analysis utilizes a matrix of squares of arbitrarily com-
puted pairwise distances in lieu of the covariance matrix
to be decomposed into within and between group sums
of squares. This decomposition is used to compute a
pseudo-F-statistic, the significance of which may be
established by permutation. Post hoc pairwise testing of
significant multilevel factors was likewise performed by
permutation. This analysis was performed using the
adonis function from the R package vegan [44].
Results
Psoriatic lesions trend to decreased taxonomic diversity
To assess the changes in α diversity related to psoriasis,
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richness and evenness at phylum, class, order, family and
genus taxonomical level, as well as at the level of OTUs
defined as sequences with 97% identity to each other. At
all taxonomical levels, the richness index demonstrated a
trend of decreasing diversity from controls to unaffected to
psoriatic lesion skin (Figure 1A). We tested the significance
of this trend at depth of 2,000 sequences per sample;
however, this trend was not statistically significant (P >0.05).
The shape of saturation curves suggests that while our data
accurately reflect genus-level and higher-level composition
of cutaneous microbiota, our data do not encompass all
subgenera-level skin taxa. In terms of evenness as measured
by the Shannon index (also known as non-normalized
Shannon equitability index) (Figure 1B), saturation was
reached faster at each taxonomic level. Lesion specimens
had less evenness (as measured by the Shannon index) than
the unaffected and control specimens; we observed statisti-
cally significant differences in evenness (P <0.05 at the
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level, P >0.05). The specimens from all three clinical skin
types share a large fraction of taxa at all taxonomical levels
(Figure 1C). Essentially no taxa uniquely characterize
any of these skin types. Decreased evenness in the lesion
microbiota along with maintenance of approximately the
same number of total taxa predict that one or more taxa
should exhibit higher relative abundance in the lesion
samples, compared to the other groups.
Psoriasis status is associated with relative abundance and
presence of specific taxa
Next, we examined the relative abundance of the taxa that
constitute the multivariate distribution of the cutaneous
microbiota. Skyline plots demonstrated generally similar
compositions of cutaneous microbiota in terms of phylum-
level relative abundance (Figure 2A) for the three groups of
specimens. We observed that three phyla: Proteobacteria,
Firmicutes, and Actinobacteria dominate the skin microbial
communities in all three skin types, consistent with
observations of previous studies of psoriasis and
healthy skin composition [2]. At the genus level (Figure 2B),
lesional specimens show similar composition to other
groups with no strongly apparent differences. We
further examined the dominant taxa (those with
mean relative abundance of ≥1%) at each taxonomic
level to assess their association with psoriasis status
(Table 1 and Additional file 1: Figure S2). Many taxa
were found to be associated with psoriasis status,
despite high variance in each clinical group. Surprisingly,
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lesion specimens.
We examined the abundances of the major skin genera
with respect to psoriasis status. Each of the major taxa
that typically are found on skin (Propionibacterium,
Corynebacterium, Streptococcus, and Staphylococcus),
were not significantly different between lesion, unaffected,
and control. However, the combined relative abundance
of these four genera was significantly (P <0.01) different
across the specimen groups. Upon further examination
Propionibacterium does not play an important role for
distinguishing skin types. Combined relative abundance of
just three genera (Corynebacterium, Streptococcus, and
Staphylococcus) attained statistical significance (P <0.05).
The mean combined relative abundance of these genera
increases from control (mean (± SEM): 22.03% (± 2.1%))
to unaffected (22.9% (± 2.5%)) to lesion (33.8% (± 3.3%))
specimens. Pairwise post hoc testing revealed that the
combined abundance of the three genera in control and
unaffected microbiota was different from lesion (P <0.05).
Likewise, the univariate classification signal, as measured
by AUC, for each of the four skin-associated taxa was not
significant, while the combined signal of all four and just
three (without Propionibacterium) as well as the univariate
signals of other named differentially abundant taxa were
stronger, approaching diagnostically relevant values
(AUC 0.65 to 0.81) (Additional file 1: Figure S3). To place
these results in context, the widely used prostate-
specific antigen (PSA) has an AUC <0.75, and for
some versions <0.65 [45]. We have further analyzed this
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Table 1 Univariate association of major taxa with psoriasis status using Kruskal-Wallis ANOVA
Taxonomic level Taxon Kruskal-Wallis
χ2
df Median abundance FDR adjusted
P valueaControl Unaffected Lesion
Phylum Bacteria;Acidobacteria 18.68 2 0.97%* 0.48%** 0.18%*** 6.14E-04
Bacteria;Deinococcus-Thermus 9.14 2 0.37%* 0.22%** 0.14%*** 2.41E-02
Bacteria;Otherb 14.27 2 2.52%* 2.20%** 1.42%*** 2.79E-03
Bacteria;Proteobacteria 7.42 2 33.32%** 36.21%* 30.75%*** 4.27E-02
Class Acidobacteria;Acidobacteria_Gp4 14.08 2 0.92%* 0.41%** 0.12%*** 4.39E-03
Bacteroidetes;Sphingobacteria 8.53 2 1.70%* 1.50%** 0.74%*** 3.52E-02
Deinococcus-Thermus;Deinococci 9.14 2 0.37%* 0.22%** 0.14%*** 3.44E-02
Proteobacteria;Alphaproteobacteria 7.63 2 16.44%* 11.37%** 7.64%*** 4.41E-02
Order Acidobacteria_Gp4;Gp4 14.08 2 0.92%* 0.41%** 0.12%*** 5.70E-03
Sphingobacteria;Sphingobacteriales 8.53 2 1.70%* 1.50%** 0.74%*** 3.05E-02
Alphaproteobacteria;Rhizobiales 11.53 2 13.63%* 7.94%** 4.11%*** 1.36E-02
Betaproteobacteria;Burkholderiales 8.80 2 9.33%** 11.61%* 5.95%*** 3.05E-02
Gammaproteobacteria;
Xanthomonadales
9.34 2 1.83%* 1.23%** 0.32%*** 3.05E-02
Family Gp4;Other 14.08 2 0.92%* 0.41%** 0.12%*** 9.22E-03
Sphingobacteriales;Chitinophagaceae 10.61 2 0.93%* 0.56%** 0.34%*** 1.74E-02
Bacillales;Bacillaceae 11.75 2 0.61%* 0.31%** 0.09%*** 1.18E-02
Rhizobiales;Bradyrhizobiaceae 12.95 2 2.21%* 1.89%** 0.73%*** 1.08E-02
Rhizobiales;Methylobacteriaceae 12.07 2 8.43%* 4.42%** 2.39%*** 1.18E-02
Burkholderiales;Burkholderiaceae 8.46 2 4.89%* 4.68%** 1.95%*** 3.82E-02
Burkholderiales;Comamonadaceae 7.71 2 2.05%* 1.64%** 0.94%*** 4.94E-02
Xanthomonadales;Xanthomonadaceae 9.61 2 1.79%* 1.23%** 0.31%*** 2.45E-02
Genus Gp4;Other 14.08 2 0.92%* 0.41%** 0.12%*** 2.98E-03
Chitinophagaceae;Flavisolibacter 14.32 2 0.22%* 0.05%** 0.02%*** 2.98E-03
Bacillaceae;Geobacillus 8.03 2 0.06%* 0.00%*** 0.00%*** 3.83E-02
Methylobacteriaceae;Methylobacterium 12.19 2 8.43%* 4.42%** 2.39%*** 5.48E-03
Burkholderiaceae;Cupriavidus 21.50 2 3.20%** 3.38%* 0.73%*** 1.83E-04
Comamonadaceae;Schlegelella 25.21 2 0.64%* 0.35%** 0.05%*** 5.71E-05
Xanthomonadaceae;Other 12.74 2 1.46%* 0.39%** 0.17%*** 4.85E-03
Operational taxonomical unit (OTU) Methylobacterium;484 15.16 2 5.51%* 2.65%** 1.22%*** 1.66E-03
Gp4;3855 16.95 2 0.72%* 0.06%** 0.00%*** 9.04E-04
Xanthomonadaceae;6162 10.04 2 1.06%* 0.16%** 0.02%*** 1.72E-02
Cupriavidus;6869 20.96 2 2.38%** 2.40%* 0.55%*** 1.83E-04
Schlegelella;13613 26.57 2 0.47%* 0.22%** 0.00%*** 2.21E-05
Methylobacterium;24283 9.11 2 1.02%* 0.74%** 0.34%*** 2.28E-02
Coding indicates high (*), intermediate (**), or low (***) abundance values in each row.
aOnly taxa significant at 5% FDR are shown.
bThis taxon represents all sequences that were not assigned to a known phylum. It is significant at all taxonomic levels.
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cible signals are possible [46].
We utilized univariate χ2 to identify individual OTUs of
potential diagnostic significance. These tests for presence/
absence of highly abundant OTUs (mean relative abun-
dance ≥1%) showed that after correction for false discoveryrate (FDR), 2 specific OTUs (out of a total of 13 highly
abundant OTUs) were strongly associated with psoriasis
status (Acidobacteria Gp4 (OTU 3,855, P <0.002) and
Schlegelella (OTU 13,613, P <0.00002). The identified
OTUs were frequently encountered in all skin types
(Additional file 1: Table S4), despite the evidence for
Table 2 Diagnostic performance of incidence-based psoriasis predictor
Group Positive for OTU (%)a Double
positiveb
Odds ratio
Acidobacteria Gp4 (3,855) Schlegelella (13,613) Lesion (95% CI) Unaffected (95% CI)
Control 80 96 78 0.073 (0.024 to 0.203) 0.329 (0.123 to 0.838)
Unaffected 61 69 53 0.220 (0.080 to 0.566)
Lesion 39 49 20
aThe only two taxa significant at 5% FDR within all OTUs with >1% mean abundance.
bχ2 = 33.9, df = 2, P value <0.0000001.
OTU operational taxonomical unit.
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combined double-positive psoriasis predictor based on
these two OTUs (representative sequences shown in
Additional file 1: Table S5) was associated with psoriasis
status (P <10-7) and achieved a diagnostically relevant
odds ratio (0.073) (95% CI 0.024 to 0.203) for distinguish-
ing lesion versus control samples (Table 2). From these
data, we conclude that it is feasible to identify strong pre-
dictive markers of psoriasis from composition of cutaneous
microbiota.
Psoriasis lesions are characterized by greater intragroup
variability
We evaluated the skin microbiota for the degree of sample-
to-sample variability using β diversity, a distance-based eco-
logical measure that allows for comparison of specimens
grouped according to skin type. The β diversity analyses
were performed, using subject site as the unit of independ-
ent analysis, however, for lack of appropriate comparison
methodology these analyses do not account for the fact that
some control subjects contributed multiple specimens
(from different sites) to the matched triplets. We expect the
intrasite differences to be greater than the differences



















































Figure 3 Intergroup and intragroup β diversity. Mean (± SEM) pairwise
methods are shown. Significance was determined by one-way analysis of v
method for correction for multiple comparisons. For the 51 triplet sets, all d
(P <0.05), except for the comparisons between control-lesion and within u
lesion. All differences between the weighted pairwise comparisons were si
and unaffected-lesion, and the comparison between unaffected-lesion andpartially alleviates this apparent loss of independence.
We chose to examine the β diversity in our data using
weighted and unweighted Unifrac dissimilarity measures
[32] based on their performance [47] in showing the
differences among clinical groups. In terms of both
measures, lesional specimens showed the highest
intragroup diversity, followed by the unaffected, and
control specimens (Figure 3). These findings indicate
that control subjects are more similar to one another in
terms of their cutaneous microbiome than the specimens
from unaffected sites of psoriasis patients, and that each
lesion harbors a more distinct community of microbes
compared to other lesions. The intergroup unweighted
Unifrac distances are smaller between lesion and control
than between lesion and unaffected sites. Similarly, the
unaffected skin is closer to the control than to lesion.
These findings suggest that the microbiota of unaffected
skin from psoriasis patients maintains many compositional
characteristics of the skin of the control subjects, while
simultaneously showing divergence from lesion skin on the
contralateral part of the body. This difference is indicated
by the substantial β diversity of the lesional microbiota.
Using the weighted Unifrac analyses, trends are similar,

























































Unifrac distances obtained by unweighted (A) or weighted (B)
ariance (ANOVA) with the Tukey honestly significant difference (HSD)
ifferences in the unweighted Unifrac comparisons were significant
naffected, and the comparison between unaffected-lesion and within
gnificant (P <0.05) except for the comparisons between control-lesion
within lesion.
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http://www.microbiomejournal.com/content/1/1/31specimens (Figure 3B). Distances in relation to the lesion
specimens are greater in relation to the control and
unaffected specimens than are the comparisons of control
and unaffected. From these findings, we conclude that
psoriasis is associated with a systemic change in the
cutaneous microbiota that is evident in both the
lesion samples and, to a lesser degree, in the clinically
unaffected skin.
The psoriatic microbiota is associated with a cutaneotype
enriched for Firmicutes and Actinobacteria
For clinical and investigational purposes, it would be
useful if the cutaneous microbiota could be stratified
into distinct subtypes. We performed a preliminary analysis
of the cutaneous microbial community data for evidence
that there might be such stratification into distinct clusters,
using the methodology previously employed to report
clustering of the gut microbiota [39]. Based on the
Calinski-Harabasz index [41], we show that the data
can be optimally separated into two clusters, which
we call cutaneotypes (Figure 4A). A representation of































































Figure 4 Evidence for psoriasis-associated cutaneotypes. (A) Clustering
two clusters, which we called cutaneotypes, can optimally describe the dat
used to select the optimal number of clusters, which also indicated that tw
phyla is different between the two cutaneotypes. (C) The distribution of sp
cutaneotype (P <0.01 based on χ2 test). Cutaneotype 2 is enriched for lesio
(OR 3.52, 95% CI 1.44 to 8.98), unaffected skin specimens are approximately
nated by Proteobacteria (D). In the density plots, the dotted line shows the
cutaneotype 2. In cutaneotype 2, Actinobacteria (E) and Firmicutes (F) are thAdditional file 1: Figure S4. These cutaneotypes differ in
terms of the relative abundance of major phyla (Figure 4B);
specifically, cutaneotype 1 is dominated by Proteobacteria
(Figure 4D), while communities of cutaneotype 2 have
higher relative abundance of Actinobacteria (Figure 4E),
and Firmicutes (Figure 4F). We notice that the distribution
of Proteobacteria is bimodal, with peaks corresponding to
the modes of the respective contributing distributions,
each linked to a cutaneotype. This suggests that changes
in Proteobacteria may be driving the clustering, while the
changes in relative abundance of the other two phyla may
be due to compositional effects. Although the actual value
of Proteobacteria relative abundance may vary continu-
ously over the domain (0% to 100%), the bimodality of
the Proteobacteria distribution serves as an important
additional piece of evidence for the presence of two
distinct clusters. The peaks of the modes correspond
to the modes of the underlying distributions. How-
ever, the exact delineation between cutaneotypes may
be difficult to define because the two distributions
contributing to the bimodal mixture have substantial






































analysis of the Jensen-Shannon divergence distances indicated that
a. The Calinski-Harabasz index plot versus the number of clusters was
o has the highest Calinski index. (B) The relative abundance of major
ecimens in the three clinical categories is significantly associated with
n specimens, while controls are more likely to be of cutaneotype 1
evenly distributed between the cutaneotypes. Cutaneotype 1 is domi-
combined density for both cutaneotypes: blue, cutaneotype 1; green,
e dominant phyla.
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ition, the cutaneotypes are associated with psoriasis status
(P <0.01). Non-lesion specimens from affected individuals
have approximately even assignment to cutaneotypes, while
most of the control specimens belong to cutaneotype 1 and
the lesional specimens are dominated by cutaneotype 2
(Figure 4C). The difference in cutaneotype composition be-
tween the lesion and control samples yields a high odds ra-
tio (3.52 (95% CI 1.44 to 8.98)). The evidence for
existence of these two distinct cutaneotypes in the
data is further corroborated by analyses based on the
gap statistic [42] (Additional file 1: Figure S5 and
Supplemental Methods section). In total, these findings
provide strong support of the existence of distinct types of
skin microbiota, cutaneotypes that differ in prevalence in
psoriasis. Cutaneotypes serve as the description of the
internal structure of our dataset, which may or may
not be reproduced in other data. We caution the reader
against overgeneralization of the reported preliminary ob-
servations to other datasets. The utility of clustering ana-
lysis rests in part on its reproducibility and generalizability;
future studies of the cutaneous microbiota should examine
this issue.
Psoriasis status is the major source of variability in
microbial communities
We next attempted to decompose the variability of the
microbiota into major components to identify possible
































Figure 5 Principal coordinates analysis (PCoA) of weighted Unifrac di
variability explained by the principal axes, we chose to represent the cutan
the scatterplot of the first two principal axes of the PCoA, each point represen
and the colored boxes are positioned at the geometrical center of all the poi
PC1 (C) and PC2 (D) are shown in the boxes (representing the middle 50% o
are significantly different from control (P <0.001) and unaffected (P <0.
honestly significant difference (HSD) multiple comparison correction.weighted Unifrac distances to examine the association of
the entire cutaneous microbiome with specimen type
(Figure 5). The first two axes are clearly separated from
the rest of the components (Figure 5A), therefore we
chose to represent the cutaneous microbiome of our
study in these two dimensions. Only approximately 24%
of total variation in the dataset is explained by the first
plane, indicating that most of the variation is captured
in multiple other dimensions. The high variability of the
composition of individual cutaneous microbiota is indicated
by the observation that 11 and 84 axes are necessary to
represent, >50% and >90%, respectively, of the variability
present in the specimen comparisons (data not shown). We
tested the first two principal coordinates for association
with psoriasis status. The microbiota from the lesions is
distinguishable from that of unaffected and control skin
along the first principal axis (Figure 5B) (P <0.001,
ANOVA). This means that the major axis of variability as
determined by Unifrac-based principal coordinates
analysis is aligned with psoriasis status. Samples from
control and unaffected skin are located across the origin
from the lesion samples on PC1, but not on PC2
(Figure 5C). The individual samples from the different
specimen types occupy common areas on two-dimensional
and three-dimensional plots, without clear clustering
according to psoriasis status. These findings reiterate
the increased diversity in the psoriasis lesions and
establish psoriasis status as one of the main sources



























stances. Based on separation of the relative values of the percentage
eous microbiome of our study in the first two components (A). (B) On
ts an individual subject (red = control, green = unaffected, blue = lesion)
nts in the corresponding groups. The distributions of the points along
f the data) and whiskers (95% interval) plots. Along PC1, lesion samples
015) based on one-way analysis of variance (ANOVA) with Tukey
Table 3 Non-Euclidean multivariate analysis of variance
Factor df Sum of
squares
Pseudo-F-statistic P valuea
Body siteb 3 1.363 1.624 0.00015
Cutaneotype 1 0.626 2.236 0.00015
SampleMonthYear 24 10.141 1.510 0.00015
Status 2 0.854 1.526 0.0003
Skin micro-environment 1 0.321 1.141 0.11000
Gender 1 0.363 1.296 0.2940
Ethnicity 3 0.972 1.158 0.3179
Age 1 0.305 1.091 1.0
History 1 0.302 1.080 1.0
Status × body site 6 1.529 0.910 1.0
Status × age 2 0.482 0.862 1.0
Status × sample
month year
28 7.265 0.927 1.0
Status × gender 2 0.468 0.837 1.0
Status × ethnicity 6 1.733 1.032 1.0
Status × history 2 0.490 0.876 1.0
Status × cutaneotype 2 0.549 0.981 1.0
Residuals 66 18.471
Total 150 45.913
aP values are based on 100,000 permutations and are adjusted for multiple
testing using the Bonferroni method. Significant values are in bold.
bBody sites are grouped into head, body, upper extremities, lower extremities.
Table 4 Post hoc analysis of body site differences
Body site comparison Sum of
squares
Pseudo-F-statistic P valuea
Body/head 0.481 1.585 0.018
Body/upper extremity 0.441 1.465 0.036
Head/lower extremity 0.599 1.959 0.006
Head/upper extremity 0.586 1.938 0.006




aP values are based on 1,000 permutations per pairwise comparison and are
adjusted for multiple testing using the Bonferroni method. Significant values
are in bold.
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http://www.microbiomejournal.com/content/1/1/31remaining variation unaccounted for by the clinical
data.
We next analyzed the cutaneous microbiota for associ-
ation with clinicodemographic variables, to identify possible
interactions with psoriasis status using non-parametric
multivariate analysis of variance (adonis) (Table 3). The
model for explaining the observed variability of the
microbial communities (β diversity) included the following
explanatory variables: psoriasis status, cutaneotype, month
and year of sampling, body site, skin microenvironment
type, age, gender, ethnicity of the subjects, and family
history of psoriasis. Interactions of the above variables
with psoriasis status were also tested.
We did not find evidence that links subject gender,
ethnicity, age, or family history of psoriasis with the
variability of the cutaneous microbiota. However, affected
body site and month of sample collection each were
associated with microbiota composition (P <0.001).
Interestingly, in our data the cutaneous microenvironment
(dry vs sebaceous) is not an important factor in accounting
for variability of the skin microbiota (P >0.05). We further
examined the association of the microbiota with the
collection date for possible biases. We re-evaluated the
model by considering only lesion and unaffected specimens
(which are collected from the same individual) and
stratifying the analyses by the subject. Under the modified
model, the month of collection was not significant,
suggesting that the association we originally observed is
entirely due to the high intersubject variability, which is
captured in part by the collection date variable.
In terms of body sites, the head harbors the most distinct
microbiota from the other sites, as expected [19,48], while
the lower and upper extremities are highly similar to each
other (Table 4). Thus, the interactions of psoriasis status
with the recorded clinicodemographic variables were not
significantly associated with the cutaneous microbiota
distribution.
Correlation analysis of psoriasis severity
An important prospect of studying the microbiota in
psoriatic lesions is to identify taxa that correlate with
disease severity, which may lead to better understanding
of microbial roles in disease progression. We examined the
identified distinct cutaneotypes for association with disease
severity, as measured by the PASI, BSA and PGA scores.
The cutaneotypes were not significantly associated with
any of these severity measures (Additional file 1: Figure S6).
However, several specific major taxa present across many
taxonomic levels are associated with severity (Table 5).
We did not find any taxa that were simultaneously
correlated with all three measures of severity. This
suggests that there is a weak link between the clinical
assessment of disease severity and microbial colonization
of the lesions.Longitudinal analysis of the cutaneous microbiota
The longitudinal basis of sample collection allowed us to
assess the effects of anti-inflammatory therapies on the
composition of the microbiota communities. The psoriasis
patients showed an overall improvement in the clinical
severity of the lesions during the course of the treatment
(Additional file 1: Table S6). Because we were only able to
obtain follow-up samples from 17 and 9 subjects at
12-week and 36-week timepoints, we used the control



































































































Figure 6 α Diversity trends in the longitudinal cohort. For the longitudinal cohort, we show the α diversity ((A,B): richness, (C,D) Shannon) of
unaffected (green) and lesion (blue) samples relative to the control group at the class level (A,C) and for 97% operational taxonomical units
(OTUs) (B,D). At all timepoints, the data show no statistically significant intergroup differences in α diversity.
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cohort demonstrated high variability in the measurements
of richness and Shannon index. Therefore, we looked for a
way to minimize the variability in the data by restricting
our analysis to triplets and viewing them in the light of
natural variability that is represented by the control
subjects. To do so, for each triplet we subtracted the
α diversity of the control specimen from those of the
unaffected and lesion specimens. The utility of this
approach is in that in our case it allowed for consistent
longitudinal trends to emerge in otherwise highly variable
data. Thus, the longitudinal α diversity results are presented
in terms of α diversity relative to the controls in each triplet
(Figure 6). Although no statistically significant difference
was observed between lesion and unaffected groups or
longitudinally within groups, we observed several consistent
patterns. Richness decreased over time (and treatment) in
both lesion and unaffected specimens at all taxonomical
levels, except for 97% identity OTUs, where the lesion
demonstrated similar decrease, while the unaffected
cutaneous flora rebounded to baseline levels at week 36.
We also observed an increase in evenness (Shannon index),
followed by a later decline. Both observations are consistent
with findings in the cross-sectional cohort and lead to the
similar conclusion that the abundance of a taxon or a groupof taxa was increased, leading to elimination of other taxa
(decreasing richness) and lower abundances of the others
(decline in evenness). These patterns are preliminary and
will require a larger cohort to confirm or reject.
The weighted and unweighted Unifrac intragroup β
diversity estimates were similar among the three groups
at all sampling times (Figure 7). Significant intragroup
differences only were observed at baseline (Figure 7A) in
case of unweighted Unifrac. One explanation for the
absence of robust statistical differences in α and β diversity
between the skin types is insufficient power in the
longitudinal study.
However, the longitudinal samples allowed us to
confirm the observation that cutaneotype 2 is most
prevalent in psoriasis subjects even in the course of
treatment. We found that although the prevalence
changed over time, the relative trend of increased
prevalence of cutaneotype 2 in unaffected and lesion
specimens was consistent at all three timepoints (Figure 8).
As can be seen from examining just the controls, subjects
may switch from cutaneotype 1 to 2 within the course of
the experiment. The source for this dynamic behavior is
unknown and cannot be determined from the data we
have, but suggests that in the skin as with other body sites
(for example, the vagina; see [3]), the major clustering
Table 5 Correlation of specific taxa with psoriasis severity
Group Subgroup PASI BSA PGA
ρ P valuea ρ P valuea ρ P valuea
Phylum Acidobacteria −0.50 0.003* −0.54 0.032* −0.33 0.080
Proteobacteria −0.33 0.087 −0.03 0.893 −0.43 0.018*
Class Acidobacteria_Gp4 −0.40 0.029* −0.20 0.688 −0.29 0.094
Sphingobacteria −0.20 0.370 −0.13 0.688 −0.37 0.039*
Alphaproteobacteria −0.25 0.244 −0.07 0.751 −0.40 0.035*
Betaproteobacteria −0.45 0.018* −0.21 0.688 −0.39 0.035*
Order Gp4 −0.40 0.038* −0.20 0.623 −0.29 0.102
Sphingobacteriales −0.20 0.344 −0.13 0.645 −0.37 0.048*
Bacillales −0.01 0.954 −0.29 0.501 0.39 0.048*
Rhizobiales −0.26 0.332 −0.11 0.645 −0.43 0.033*
Sphingomonadales −0.20 0.344 0.04 0.847 −0.34 0.049*
Burkholderiales −0.43 0.036* −0.29 0.501 −0.36 0.048*
Family Methylobacteriaceae −0.22 0.491 −0.12 0.856 −0.42 0.038*
Comamonadaceae −0.22 0.491 0.07 0.902 −0.51 0.005*
97% OTU Methylobacterium;484 −0.22 0.346 −0.16 0.705 −0.38 0.036*
Gp4;3855 −0.45 0.022* 0.05 0.952 −0.32 0.085
Schlegelella;13613 −0.04 0.927 0.20 0.705 −0.39 0.036*
Methylobacterium;24283 −0.15 0.704 −0.08 0.912 −0.40 0.036*
aOnly taxa that are significant at 5% FDR (*) for at least one measure of severity are shown.
BSA body surface area, OTU operational taxonomical unit, PASI Psoriasis Area and Severity Index, PGA physician global assessment.
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http://www.microbiomejournal.com/content/1/1/31types may shift for an individual. This may be an import-
ant observation. This serves as an initial evidence of utility
of cutaneotype clustering, which needs to be further
examined in the future. A possible limitation to this
observation is that the apparent increase in the proportion
of cutaneotype 2 samples may in part be due to decreasing
number of triplets over time in the longitudinal cohort
(17 at baseline and 12-week mark and 9 at 36-week mark).
























Figure 7 Intragroup β diversity trends in the longitudinal cohort. (A)
β diversity at three timepoints in relation to treatment of the patients with
(*) indicates comparisons that are significant at the 5% α level.We also examined the longitudinal stability of the
observed differential abundance of skin-associated genera
(Corynebacterium, Propionibacterium, Staphylococcus, and
Streptococcus). We found that the total combined relative
abundance of these taxa remained surprisingly stable in
the control specimens throughout the course of the
experiment, while their abundance in the lesion and
unaffected samples varied over time and was consistently
different from that of control (Figure 9). The lesion speci-


















Unweighted, and (B) weighted intragroup Unifrac distances. We show



























Figure 8 Distribution of the longitudinal samples in cutaneotype
2. The cutaneotype prevalence in the longitudinal cohort reflects
that of the cross-sectional study (Figure 5C). Cutaneotype 2 is most
prevalent in the unaffected and lesion specimens. The frequency of
cutaneotype 2 is significantly different (P <0.005, Fisher exact test) at
week 12 in control vs lesion and in control vs unaffected specimens.




























Figure 9 Relative abundance of skin-associated genera in
longitudinal samples. The combined abundance (± SEM) of four
skin-associated genera (Corynebacterium, Propionibacterium,
Staphylococcus and Streptococcus) is shown over the course of the
longitudinal study in three skin types. Control skin demonstrates a
stable relative abundance of these bacteria, while variability is evident
in unaffected and lesion skin. Lesional microbiota shows a dramatic
increase in these bacteria at all timepoints.
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http://www.microbiomejournal.com/content/1/1/31to these skin genera, and that proportion increased slightly
from 40.9% at baseline to 46.7% at week 36. The abun-
dance of these bacterial genera in the unaffected skin
(25.5%) was similar to the control (27.8%) at baseline,
but increased dramatically after 12 weeks of treatment
(52.3%) before declining (37.1%) after further 24 weeks of
treatment. This suggests that normally stable microbiota
are perturbed by the treatment. A larger cohort of subjects
is needed to examine the clinical significance, strength,
and stability of such perturbation.
Discussion
Although the taxa represented in control, unaffected, and
lesion sites are highly similar, regular patterns were ob-
served, which we captured as cutaneotypes. This definition
of cutaneotypes is potentially useful, but must be confirmed
in subsequent studies with larger populations and longer
follow-up. It is particularly promising that we are able to
associate the Firmicutes and Actinobacteria-rich cutaneo-
type with psoriasis status, an association that also is
maintained in our small-scale longitudinal study.
Further promising evidence of the utility of examining
the cutaneous microbiome for markers of disease is
provided by identifying differential colonization of the
major skin taxa (Corynebacterium, Propionibacterium,
Staphylococcus, and Streptococcus), not only in the lesions,
but also on the unaffected skin. The increase in the
combined relative abundance of these genera in psoriasis
is complemented by decreases in other genera, such as
Cupriavidus, Methylobacterium, and Schlegelella, whichall carry a strong diagnostic signal pertinent to the disease.
The absence of two specific OTUs (Gp4 and Schlegellela)
likewise provides an independent strong binary diag-
nostic signal. These two taxa, which correlated best
with psoriasis, Gp4 and Schlegelella, were either not
found in the HMP subjects [4] (Gp4), or found only
rarely (in 3 of 664 samples). Although they may be
transients or contaminants, they may also serve as
markers of decreased diversity associated with abnormal
conditions in the skin of psoriasis patients and specifically
at the lesion sites. The four-genera abundance-based
biomarker appears to capture similar information afforded
by the discovered cutaneotypes, while the double-positive
binary predictor is not driven by the cutaneotype struc-
ture. Although associations of specific taxa with disease
severity were not robust, we predict that cutaneous micro-
biota composition will provide additional insight to under-
stand mechanistic aspects of the continued cutaneous
immune response.
The HMP study of healthy individuals yielded only
low levels of cutaneous Proteobacteria [19], differing
from both our own clinical observations and other studies
in psoriasis [2]. Cutaneotype 1, most prevalent in our
healthy control subjects, tends to have high Proteobacteria
abundance. That overall composition in our controls
differed from the healthy persons in the main HMP cohort
could reflect differences in geography, climate, study
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as well as sequencing and analytical methodologies.
However, the sampling, sequencing, and analytic pipelines
were nearly identical to the HMP protocol.
The longitudinal studies also indicate that the psoriasis
treatments reduce richness and increase evenness, at
least transiently, in both the lesion and the unaffected
cutaneous communities. Since the treatments are systemic
and not local, such a generalized response was expected;
nevertheless, its presence further validates our initial
findings. The extreme dynamism of the major genera
in the clinically unaffected skin with early treatment
vis a vis the lesion sites indicates substantial instability or
transition state at such sites.
Prior studies of the cutaneous microbiota have indicated
extensive interindividual variability [2,6-8,11-16], especially
in relation to other body sites, as shown by the HMP data
[19]. The comparison of lesional and unaffected specimens
from the same subject in our study mitigates this issue.
The necessary comparisons between diseased and control
subjects are affected by the interindividual variation;
inclusion of 51 pairs helps control for this, but even larger
study sizes would be better. That the clinically unaffected
samples are interposed between control and lesion in
our analyses, provide some confidence in the biologic
plausibility of our approach and interpretations.
Conclusions
In this work, we present the first comprehensive analysis
of the community structure of the cutaneous microbiota
in psoriasis patients. Although we analyzed the data for
51 triplets of control, unaffected, and lesion specimens,
the inherent heterogeneity of the skin microbiota [19] as
well as the heterogeneity of the disease [1,2,5] requires
still-larger datasets to strengthen our conclusions.
Nonetheless, our robust triplet study design and rigorous
exclusion criteria that preclude subjects with recent relevant
or antibiotic treatment, allowed us to perform a preliminary
examination of the changes in the microbial ecology of
cutaneous sites in response to psoriasis.
Consistent decreases of taxonomic and species (OTU)
level diversity in terms of both evenness and richness
provide evidence that psoriasis is a stress condition that
selects against the normally present cutaneous bacterial
diversity. Importantly, the effect is observed not only at
the affected sites (lesion), but also at the clinically
unaffected contralateral skin site (unaffected), albeit to a
lesser degree. These observations indicate that psoriasis
is a condition that affects the composition of the micro-
biota as a whole, leading to shifts of the clinically
unaffected microbiota toward that of the lesions, and
not specifically limited to the lesion sites.
The skin sites showed a progressive increase in intragroup
diversity from control to unaffected to lesion. This observedincrease in specimen heterogeneity obtained from affected
individuals provides further evidence for ecosystem
disruption in the clinically unaffected sites, and indicates the
multiple cutaneous responses to the selectional stress
introduced by the psoriatic immunopathophysiology
[49-53]. Diseased tissue selects for different microbiota
than healthy, resulting from altered physical, clinical, and
immunological properties. The differential compositions
that we observed are a priori evidence for the power of
disease-specific selection. Another plausible but less likely
or exciting alternative is that the lesion sites serve as the
reservoirs for transfer of the microbes to the unaffected
skin sites by scratching, touching, washing or clothes,
which result in apparent decrease in diversity at these
sites. The design of our study does not provide for a
means for distinguishing between these two hypotheses.
Despite many limitations inherent to such observational
studies, our findings advance understanding of the effects
of psoriasis on the compositional status of the cutaneous
microbiota. We find substantial impact, which if confirmed,
may have important diagnostic, preventive, and potentially
therapeutic implications. Future studies might also include
metagenomic and metatranscriptomic analyses if limitations
in DNA quantity and quality from cutaneous samples do
not become a significant impediment.
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